ODI Pharma AB (ODI.ST)

SEK 2.76

(-8.0%)

Gross Profit Summary of ODI Pharma AB

  • ODI Pharma AB's latest annual gross profit in 2023 was -1.34 Million SEK , up 79.16% from previous year.
  • ODI Pharma AB's latest quarterly gross profit in 2023 FY was -1.34 Million SEK , up 79.16% from previous quarter.
  • ODI Pharma AB reported a annual gross profit of -6.43 Million SEK in annual gross profit 2022, up 10.96% from previous year.
  • ODI Pharma AB reported a annual gross profit of -7.23 Million SEK in annual gross profit 2021, down -103557.29% from previous year.
  • ODI Pharma AB reported a quarterly gross profit of 1.45 Million SEK for 2023 Q3, up 178.42% from previous quarter.
  • ODI Pharma AB reported a quarterly gross profit of -1.17 Million SEK for 2023 Q1, up 55.22% from previous quarter.

Annual Gross Profit Chart of ODI Pharma AB (2023 - 2018)

Historical Annual Gross Profit of ODI Pharma AB (2023 - 2018)

Year Gross Profit Gross Profit Growth
2023 -1.34 Million SEK 79.16%
2022 -6.43 Million SEK 10.96%
2021 -7.23 Million SEK -103557.29%
2020 -6975.00 SEK 43.13%
2019 -12.26 Thousand SEK -482.89%
2018 -2104.00 SEK 0.0%

Peer Gross Profit Comparison of ODI Pharma AB

Name Gross Profit Gross Profit Difference
AcuCort AB 6.59 Million SEK 120.352%
AlzeCure Pharma AB (publ) -476 Thousand SEK -181.856%
BioGaia AB (publ) 950.19 Million SEK 100.141%
Enzymatica AB (publ) 31.86 Million SEK 104.211%
Enorama Pharma AB (publ) -3.9 Million SEK 65.608%
Gabather AB (publ) - SEK Infinity%
Klaria Pharma Holding AB (publ.) -9000.00 SEK -14807.056%
Moberg Pharma AB (publ) -2.09 Million SEK 36.082%
Nanexa AB (publ) 59.15 Million SEK 102.268%
Newbury Pharmaceuticals AB (publ) 16.03 Million SEK 108.368%
Orexo AB (publ) 549.9 Million SEK 100.244%
Probi AB (publ) 220.21 Million SEK 100.609%
Swedencare AB (publ) 164.8 Million SEK 100.814%
Swedish Orphan Biovitrum AB (publ) 14.05 Billion SEK 100.01%
Toleranzia AB -919 Thousand SEK -45.989%
Vivesto AB -10.65 Million SEK 87.41%